Astrazeneca PLC ($AZN) Stock Forecast: Up 5.9% Today

What is Astrazeneca PLC?

AstraZeneca (AZN) is a pharmaceutical company listed on the NASDAQ. The company is known for its focus on oncology and respiratory drugs.

Why is Astrazeneca PLC going up?

AZN stock is up 5.9% on Feb 6, 2025 14:42

• AstraZeneca reported strong Q4 earnings with revenue exceeding expectations, particularly driven by higher sales in oncology and respiratory drugs.
• Despite facing potential fines in China, the company's positive financial outlook for FY25, projecting revenue growth and EPS growth, boosted investor confidence.
• The multiple class action lawsuits against AstraZeneca seem to have had minimal impact on the stock price, indicating that investors are more focused on the company's operational performance and future prospects.
• Overall, the bullish movement in AstraZeneca's stock today can be attributed to the robust Q4 earnings report and optimistic guidance for the future, outweighing any legal challenges the company currently faces.

AZN Price Chart

AZN Technical Analysis

AZN News

AstraZeneca Q4 Earnings: Revenue And EPS Beat On Higher Cancer And Respiratory Drug Sales, Faces $4.5 Million Potential Fine In China - AstraZeneca ( NASDAQ:AZN )

AstraZeneca Q4 revenue rose 18% to $14.89 billion, surpassing estimates, with oncology sales up 27% to $6.34 billion. FY25 guidance projects high single-digit revenue growth and low double-digit core EPS growth. NOW OPEN: 200 Charter Memberships to Benzinga Trade Alerts

https://www.benzinga.com/general/biotech/25/02/43527514/astrazeneca-q4-earnings-revenue-and-eps-beat-on-higher-cancer-and-respiratory-drug-sales-faces-4-

DEADLINE ALERT for KSPI, CPRI, AZN, RIG: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions - AstraZeneca ( NASDAQ:AZN ) , Capri Holdings ( NYSE:CPRI )

BENSALEM, Pa., Feb. 05, 2025 ( GLOBE NEWSWIRE ) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.

https://www.benzinga.com/pressreleases/25/02/g43501808/deadline-alert-for-kspi-cpri-azn-rig-law-offices-of-howard-g-smith-reminds-investors-of-opportunit

Lowey Dannenberg Notifies AstraZeneca PLC ( "AstraZeneca" or the "Company" ) ( NASDAQ: AZN ) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the Firm - AstraZeneca ( NASDAQ:AZN )

NEW YORK, Feb. 04, 2025 ( GLOBE NEWSWIRE ) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against AstraZeneca PLC ( "AstraZeneca" or the "Company" ) AZN for violations of the federal securities laws ...

https://www.benzinga.com/pressreleases/25/02/g43473837/lowey-dannenberg-notifies-astrazeneca-plc-astrazeneca-or-the-company-nasdaq-azn-investors-of-secur

AstraZeneca PLC Class Action: The Gross Law Firm Reminds AstraZeneca Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 21, 2025 - AZN - AstraZeneca ( NASDAQ:AZN )

NEW YORK, Feb. 03, 2025 ( GLOBE NEWSWIRE ) -- The Gross Law Firm issues the following notice to shareholders of AstraZeneca PLC AZN. Shareholders who purchased shares of AZN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

https://www.benzinga.com/pressreleases/25/02/g43440320/astrazeneca-plc-class-action-the-gross-law-firm-reminds-astrazeneca-investors-of-the-pending-class

Seeking Clues to Astrazeneca ( AZN ) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Astrazeneca (AZN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.

https://www.zacks.com/stock/news/2408266/seeking-clues-to-astrazeneca-azn-q4-earnings-a-peek-into-wall-street-projections-for-key-metrics

Trending Today

Shiba Inu ($SHIB) Crypto Forecast: Down 6.0% Today

Cardano ($ADA) Crypto Forecast: Down 6.3% Today

Sui ($SUI) Crypto Forecast: Down 5.1% Today

Dogecoin ($DOGE) Crypto Forecast: Down 7.0% Today

XRP ($XRP) Crypto Forecast: Down 5.2% Today

POL (Polygon) ($POL) Crypto Forecast: Down 5.1% Today

Mantle ($MNT) Crypto Forecast: Down 5.1% Today

Sei ($SEI) Crypto Forecast: Up 5.2% Today

Avalanche ($AVAX) Crypto Forecast: Down 6.1% Today

Sonic (prev. FTM) ($S) Crypto Forecast: Up 6.6% Today

Astrazeneca PLC Price History

30.09.2024 - AZN Stock was down 5.3%

• AstraZeneca's stock had a bearish movement despite the positive news of an exclusive worldwide license agreement with Monopar Therapeutics for ALXN-1840 to potentially treat Wilson disease.
• The market may have reacted negatively due to broader economic concerns impacting the pharmaceutical sector or profit-taking after a recent surge in the stock price.
• Investors might be cautious about the long-term implications of the agreement and its potential impact on AstraZeneca's financials.

05.10.2024 - AZN Stock was down 6.6%

• Despite the positive unveiling of early data from a weight loss drug partnership, AstraZeneca's stock experienced a bearish movement.
• The bullish stance taken by smart money in AZN options indicates a positive outlook, but the market movement suggests otherwise.
• It is possible that the market was expecting more substantial results or developments from the weight loss drug data, leading to disappointment and a bearish trend in the stock price.
• Investors may have been anticipating a stronger performance from AstraZeneca compared to the market, resulting in the stock trailing behind despite the positive data shared at the ObesityWeek 2024 event.

05.10.2024 - AZN Stock was down 6.6%

• Smart money investors have taken a bullish stance on AstraZeneca, as seen in the options market, but this did not translate into a positive movement in the stock price today.
• AstraZeneca unveiled early data from a Chinese-firm partnered oral weight loss drug, which could have generated mixed reactions from investors leading to the bearish movement.
• Despite a slight rise in the stock price, AstraZeneca still trailed the overall market, indicating that the news about the weight loss drug may not have been enough to offset other negative factors impacting the stock.

05.10.2024 - AZN Stock was down 7.1%

• The detention of current and former employees by Chinese authorities for alleged illegal activities in the pharmaceutical sector could have raised concerns among investors, leading to a bearish sentiment.
• Despite the positive unveiling of early data from a partnered oral weight loss drug, the overshadowing negative news regarding the investigation into potential data privacy law breaches might have impacted the stock negatively.
• The bullish stance taken by smart money in AZN options might not have been enough to counterbalance the negative sentiment stemming from the legal issues, resulting in the bearish movement.
• While the stock closed slightly higher in the most recent trading session, it still trailed the overall market performance, indicating that the concerns surrounding the investigation might be weighing down on investor confidence.

06.01.2025 - AZN Stock was up 5.9%

• AstraZeneca reported strong Q4 earnings with revenue exceeding expectations, particularly driven by higher sales in oncology and respiratory drugs.
• Despite facing potential fines in China, the company's positive financial outlook for FY25, projecting revenue growth and EPS growth, boosted investor confidence.
• The multiple class action lawsuits against AstraZeneca seem to have had minimal impact on the stock price, indicating that investors are more focused on the company's operational performance and future prospects.
• Overall, the bullish movement in AstraZeneca's stock today can be attributed to the robust Q4 earnings report and optimistic guidance for the future, outweighing any legal challenges the company currently faces.

16.03.2024 - AZN Stock was down 0.7%

• Promising data from the TOPAZ-1 Phase 3 trial of Imfinzi in combination with chemotherapy for biliary tract cancer was released, showing positive long-term overall survival results.
• Despite the positive news, the market may have reacted bearishly due to broader market conditions or profit-taking after recent gains.
• The volume spike in Aster DM Healthcare Ltd and other stocks could indicate shifting investor interest away from pharmaceuticals temporarily, impacting AZN's stock negatively.
• A warning shot fired by L%26G at AstraZeneca over executive pay could have also contributed to the bearish sentiment surrounding the stock.